Table 3. Biochemical pro-inflammatory/pro-atherothrombotic evaluation according to TKI treatment at study visit.
| imatinib whole cohort | nilotinib whole cohort | p | imatinib (previously treated with nilotinib) | P (vs. always treated with imatinib n. 58) | |
|---|---|---|---|---|---|
| N° Patients | 65 | 45 | 7 | ||
| oxLDL (UI/L) | 69.9±7.1 | 92.2±9.9 | 0.0022 | 71.4±8.8 | 0.097 |
| IL6 (pg/ml) | 8.8±1.33 | 9.9±1.44 | 0.091 | 8.5±1.67 | 0.094 |
| IL10 (pg/ml) | 4.86±1.17 | 1.06±0.58 | 0.00012 | 4.59±1.23 | 0.081 |
| TNFα (pg/ml) | 9.6±1.8 | 10.8±1.93 | 0.094 | 9.9±1.9 | 0.088 |
| sCD40L (pg/ml) | 330.5±59.2 | 513.3±91.9 | 0.0023 | 336.4±55.2 | 0.090 |
| ETP (%) | 7.3±1.82 | 14.7±3.73 | 0.0019 | 7.4±1.93 | 0.104 |
| hs-CRP (mg/dl) | 1.02±0.17 | 1.14±0.21 | 0.076 | 1.09±0.14 | 0.070 |
Abbreviation: oxLDL oxidized-LDL, IL interleukin, TNFα tumor necrosis factor alpha, sCD40L soluble CD40 ligand, ETP Endogenous Thrombin Potential, hs-CRP high-sensibility C reactive protein.